Halozyme Therapeutics HALO Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total cost of revenue?
- Halozyme Therapeutics (HALO) reported total cost of revenue of $79.24M in Q1 2026.
- How has Halozyme Therapeutics's total cost of revenue changed year-over-year?
- Halozyme Therapeutics's total cost of revenue increased by 63.7% year-over-year, from $48.4M to $79.24M.
- What is the long-term trend for Halozyme Therapeutics's total cost of revenue?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's total cost of revenue has grown at a 29.5% compound annual growth rate (CAGR), from $81.41M to $228.77M.
- What does total cost of revenue mean?
- The direct costs incurred to produce the products or services that a company sells.
- How do you interpret total cost of revenue?
- An increase relative to revenue suggests margin compression, while a decrease relative to revenue indicates improved production efficiency.
- How does total cost of revenue compare across companies?
- Varies significantly by industry; biotech companies often have lower cost of revenue compared to manufacturing firms due to high-margin intellectual property.